Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has provided informed consent prior to initiation of any study specific activities/procedures.~* Participant is aged between 18 and 75.~* Fulfills classification criteria for systemic lupus erythematosus (SLE) according to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE with antinuclear antibody ≥ 1:80 by immunofluorescence on Hep-2 cells being present at screening.~* Hybrid SLEDAI score ≥ 6 points with a Clinical hSLEDAI score ≥ 4 points. The Clinical hSLEDAI is the hSLEDAI assessment score without the inclusion of points attributable to laboratory results, including urine or immunologic parameters.~* British-Isles Lupus Assessment Group (BILAG) index score (BILAG 2004) of ≥ 1 A item or ≥ 2 B items.~* Must be taking ≥ 1 of the following SLE treatments (or regional equivalent): hydroxychloroquine, chloroquine, quinacrine, mycophenolate mofetil, azathioprine, methotrexate, dapsone, or oral calcineurin inhibitors, or OCS. A participant may enter the study on OCS alone (prednisone ≥ 10 mg/day or equivalent) only if the participant has previously documented trial of anti-malarial or immunosuppressant treatment for SLE. Participants must be on a stable dose for ≥ 8 weeks prior to screening for all antimalarials and immunosuppressants, with the exception of OCS doses which must be stable for ≥ 2 weeks prior to screening.~* For participants taking OCS, dose must be ≤ 20 mg/day of prednisone or OCS equivalent, and the dose must be stable at baseline visit and for ≥ 2 weeks prior to screening visit.~* Stability of SLE treatments: OCS and other immunosuppressants/immunomodulator agents and doses must be stable since screening visit.~* Disease activity: active disease as indicated by clinical hSLEDAI score ≥ 4 must be observed (clinical hSLEDAI score is the hSLEDAI assessment score without the inclusion of points attributable to laboratory results including urine and immunologic parameters).~Exclusion Criteria:~* Lupus nephritis if any of the following are present: urine protein creatinine ratio ≥ 2000 mg/g (or equivalent) at screening, OR requiring induction therapy currently or within 1 year prior to screening, OR histological evidence (if available) of diffuse proliferative glomerulonephritis within 12 weeks prior to screening.~* Active CNS lupus within 1 year prior to screening including, but not limited to, aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.~* Currently present or within 1 year prior to screening a diagnosis of any chronic inflammatory disease other than SLE (eg, rheumatoid arthritis) which would interfere with SLE disease assessment.~* History of any disease other than SLE that has required treatment with oral or parenteral corticosteroids for \> 2 weeks within 4 months prior to screening.~* Active infection (including chronic or localized infections) for which anti-infectives are indicated currently or within 4 weeks prior to screening visit OR presence of serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to screening visit.~* Active tuberculosis or latent tuberculosis with no documented past history of adequate treatment per local standard of care.~* Positive test for tuberculosis during creening defined as: either a positive or indeterminate QuantiFERON®-TB or T-spot test OR positive purified protein derivative (PPD) (≥5 mm of induration at 48 to 72 hours after test is placed).~* Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb). A history of hepatitis B vaccination without history of hepatitis B infection (ie, positive hepatitis B surface antibody (HBsAb), negative HBsAg and negative HBcAb) is allowed.~* Positive for hepatitis C antibody.~* Known history of HIV or positive HIV test at screening.~* Presence of 1 or more significant concurrent medical conditions, including but not limited to the following:~  * poorly controlled diabetes (hemoglobin A1C \> 7) or hypertension~ * symptomatic heart failure (New York Heart Association class III or IV)~ * myocardial infarction or unstable angina pectoris within the past 12 months prior to screening~ * severe chronic pulmonary disease requiring oxygen therapy~ * multiple sclerosis or any other demyelinating disease~* Any history of malignancy with the following exceptions:~* resolved non-melanoma skin cancers \> 5 years prior to screening~* resolved cervical carcinoma \> 5 years prior to screening~* resolved breast ductal carcinoma in situ \> 5 years of screening~* Currently receiving or had treatment with: cyclophosphamide, chlorambucil, nitrogen mustard, or any other alkylating agent within 6 months prior to screening or sirolimus within 4 weeks prior screening.~* Currently receiving or had treatment with a Janus kinase (JAK) inhibitor within 3 months or less than 5 drug half-lives (whichever is longer) prior to screening.~* Currently receiving or had treatment with an immune checkpoint inhibitor (eg, programmed death 1 \[PD-1\] inhibitor, programmed death ligand 1 \[PD-L1\] inhibitor, cytotoxic T-lymphocyte associated protein 4 \[CTLA-4\] inhibitor).~Note: Abatacept is not considered a CTLA-4 inhibitor and is referred to below.~* Currently receiving or had treatment within 12 months prior to screening with T-cell depleting agents (eg, antithymocyte globulin, Campath).~* Currently receiving of had treatment with an interleukin 2 (IL-2) based therapy (eg, Proleukin).~* Current or previous treatment with a biologic agent with immunosuppressive/immunomodulatory activity as follows: rituximab within 6 months prior to screening; abatacept and belimumab within the past 3 months prior to screening; other biologics within \< 5 drug half lives prior to screening.~* Participants who have received intraarticular, intralesional, or intramuscular corticosteroids within 2 weeks prior to screening or intravenous corticosteroids within 6 weeks prior to screening.~* Participants who have received live vaccines within 5 weeks prior to screening, or plan to receive live vaccines during the treatment period and up to 6 weeks after the end of treatment period in the study.~* Currently receiving treatment in another investigational device or drug study.~* Ending a treatment with an investigational drug or investigational device less than 3 months or 5 half-lives from the last dose of the investigational drug (whichever is longer) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Standard of Care (Type: PLACEBO_COMPARATOR): None
- Efavaleukin Alfa Dose Level One + Standard of Care (Type: EXPERIMENTAL): None
- Efavaleukin Alfa Dose Level Two + Standard of Care (Type: EXPERIMENTAL): None
- Efavaleukin Alfa Dose Level Three + Standard of Care (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).